Bkw Ag (0QQ0) News

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx announces results of Annual General Meeting of Shareholders

May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global...

argenx to Present at BofA Securities 2024 Health Care Conference

May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

         RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...